Mentari Therapeutics Inc(MTRI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
AI-drawn chart patterns are for reference only.
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -31.06 | Insider Own | - | Shs Outstand | 52.8M | Perf Week | -20.97% |
| Market Cap | 0.78B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.6M | Perf Month | 10.53% |
| Enterprise Value | 0.78B | PEG | - | EPS next Q | - | Inst Own | 12.56% | Short Float | 0.14% | Perf Quarter | 2.8% |
| Income | -0.01B | P/S | 946.79 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.35 | Perf Half Y | -14.53% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -158.97% | Short Interest | 0.01M | Perf YTD | 38.68% |
| Book/sh | -2.18 | P/C | 687.05 | EPS past 3/5Y | 63.64% 66.67% | ROE | -224.38% | 52W High | -36.91% ($23.30) | Perf Year | 17.6% |
| Cash/sh | 0.02 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 155.65% ($5.75) | Perf 3Y | -81.85% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 55.05% | Gross Margin | -71.9% | Volatility(W/M) | 15.74% 16.84% | Perf 5Y | -99.84% |
| Dividend TTM | - | EV/Sales | 945.41 | Sales Y/Y TTM | -82.91% | Oper. Margin | -1238.62% | ATR (14) | 2.26 | Perf 10Y | -99.94% |
| Dividend Ex-Date | - | Quick Ratio | 0.5 | EPS Q/Q | 2.41% | Profit Margin | -1657.72% | RSI (14) | 47.11 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.5 | Sales Q/Q | -100% | SMA20 | -8.91% ($16.14) | Beta | 0.95 | Target Price | $33.75 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/3 | SMA50 | 1.02% ($14.55) | Rel Volume | 4.71 | Prev Close | $15.24 |
| Employees | 6 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | 18.27% ($12.43) | Avg Volume(3M) | 0.02M | Price | $14.7 |
| IPO | 2008/11/17 | Option/Short | No/Yes | Trades | 558 | Volume | 85,157 | Change | -3.57% |
💊 A clinical-stage biotechnology company developing antibody therapies for migraine prevention. Following its merger with InMed Pharmaceuticals, it trades on the Nasdaq under the ticker $MTRI and is headquartered in Waltham, Massachusetts, USA. Its primary candidates include a monoclonal antibody targeting pituitary adenylate cyclase-activating polypeptide and a bispecific antibody targeting both that and calcitonin gene-related peptide.
Over the past 1 year, roughly in the middle
37% below its 1-year high.
Traded more than usual. That is 471% of its average volume.
MTRI has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $94,679. Peers typically go for $1,030.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +47% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 12.6%.
Tap to view numbers
It ranks #166 of 598 in the industry
Based on market cap of $776M.
FAQ
MTRI belongs to the Healthcare sector and operates in the Biotechnology industry.
The market cap of MTRI is approximately $776M, ranking 2,684 within its sector.
MTRI has recorded a 52-week high of $23.30 and a low of $5.75.